Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Nucl Med Biol ; 36(2): 107-16, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19217522

RESUMEN

INTRODUCTION: Noninvasive early detection of beta-amyloid (Abeta) plaques might be useful for the treatment of patients with Alzheimer's disease (AD). We herein describe the synthesis of (18)F-labeled benzylideneaniline derivatives using a novel labeling approach for imaging Abeta plaques in AD patients. METHODS: Benzylidenaniline derivatives were synthesized by reacting fluorobenzaldehyde and corresponding aniline derivatives. Fluorobenzaldehyde was labeled with (18)F by incubating [(18)F]fluoride with N,N,N-trimethylbenzaldehyde in the presence of tetrabutylammonium bicarbonate. In vitro binding assay, stability test and biodistribution study were performed. RESULTS: These compounds were stable at alkaline pH (pH >9); however, they were hydrolyzed rapidly at physiological pH (pH approximately 7.4). The K(i) values of amine-containing benzylideneaniline derivatives for Abeta(1-40) and Abeta(1-42) aggregates were 26-78 nM. These (18)F-labeled benzylideneaniline derivatives showed high brain uptake and rapid clearance after intravenous administration in normal mice (1.8-3.1%ID/g at 2 min and 0.1-1.2%ID/g at 30 min). The low level of bone activity at 30 min indicated that these (18)F-labeled benzylideneanilines are not prone to defluorination. Furthermore, the compounds have suitable lipophilicity - a property required to penetrate the blood-brain barrier. CONCLUSION: These results showed that the instability of these compounds could cause a higher early phase/late phase ratio due to rapid clearance in the normal brain. The findings from this study suggest that these (18)F-labeled benzylideneaniline derivatives are feasible for the imaging of Abeta plaques.


Asunto(s)
Enfermedad de Alzheimer/diagnóstico por imagen , Compuestos de Bencilideno/metabolismo , Radioisótopos de Flúor , Placa Amiloide/diagnóstico por imagen , Radiofármacos , Péptidos beta-Amiloides/metabolismo , Animales , Barrera Hematoencefálica , Estabilidad de Medicamentos , Ligandos , Masculino , Ratones , Ratones Endogámicos ICR , Fragmentos de Péptidos/metabolismo , Tomografía de Emisión de Positrones , Radiofármacos/química , Radiofármacos/farmacocinética , Distribución Tisular
2.
Appl Radiat Isot ; 65(1): 64-9, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17010628

RESUMEN

A lipiodol solution of (188)Re-4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol ((188)Re-HDD/lipiodol) is in clinical study for liver cancer therapy. However, formulation of it is difficult due to highly active and unstable sulfhydryl groups. We produced new kits using diacetylated HDD (AHDD), in which sulfhydryl groups are protected. We found that AHDD kit can replace HDD kit due to an increased stability for formulation, the better radiolabeling efficiency (78%) and the equivalent biodistribution pattern in mice.


Asunto(s)
Aceite Yodado/síntesis química , Aceite Yodado/farmacocinética , Marcaje Isotópico/instrumentación , Compuestos Organometálicos/síntesis química , Compuestos Organometálicos/farmacocinética , Juego de Reactivos para Diagnóstico , Acetilación , Animales , Diseño de Equipo , Análisis de Falla de Equipo , Aceite Yodado/uso terapéutico , Marcaje Isotópico/métodos , Tasa de Depuración Metabólica , Ratones , Especificidad de Órganos , Compuestos Organometálicos/uso terapéutico , Radiofármacos/síntesis química , Radiofármacos/farmacocinética , Radiofármacos/uso terapéutico , Distribución Tisular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA